Clinical Trials Sponsored by LaSanta S A S

Total 2532 results

H. Lundbeck A/S

Terminated

Safety and Tolerability of Lu AF95245 in Healthy Young Men

Healthy

Netherlands
Novo Nordisk A/S

Completed

Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period (guardian 10)

Congenital Bleeding Disorder | Haemophilia A

India
Novo Nordisk A/S

Completed

Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function

Growth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone Deficiency

Germany
Novo Nordisk A/S

Completed

Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device (GoBolus)

Diabetes | Diabetes Mellitus, Type 1 Diabetes

Germany
Novo Nordisk A/S

Completed

Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting (SCALE™ IBT)

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin (PIONEER 8)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Japan, Puerto Rico, Canada, France, Mexico, Poland, Russian Federation, Greece
H. Lundbeck A/S

Terminated

Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD

Alzheimer Disease

Finland, Sweden
Novo Nordisk A/S

Completed

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment (PIONEER 5)

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Poland, Russian Federation, United Kingdom, Denmark, Finland, Sweden
Novo Nordisk A/S

Completed

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN 8)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, United Kingdom, Canada, Sweden, Ireland, Argentina, Brazil, Lebanon, Malaysia, Mexico, Italy
Novo Nordisk A/S

Completed

A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)

Diabetes Mellitus, Type 2

Germany
RSP Systems A/S

Completed

Non-invasive Glucose Measurement With Raman Technology in Patients With Type 1 and Type 2 Diabetes

Diabete Mellitus | Medical Device

Germany
H. Lundbeck A/S

Terminated

Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease

Alzheimer Disease

Austria, Finland, Sweden
Novo Nordisk A/S

Completed

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus (DUAL™ VIII)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Italy, Mexico, Poland, Russian Federation, Slovakia, United Kingdom, Argentina, Norway, Turkey, Israel, Czechia, South Africa, Hungary, Brazil
Novo Nordisk A/S

Completed

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes (Onset® 5)

Diabetes | Diabetes Mellitus, Type 1

United States, Russian Federation, United Kingdom, Canada, France, Netherlands, Belgium, Germany, Slovenia
Novo Nordisk A/S

Completed

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Russian Federation, Serbia, Turkey, Algeria, Czechia
Novo Nordisk A/S

Completed

A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh, Indonesia, Malaysia, Philippines, Sri Lanka and Vietnam (DiabCare Asia)

Diabetes Mellitus, Type 2 | Diabetes

Vietnam
Novo Nordisk A/S

Completed

Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus (ReFLeCT)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Switzerland, Denmark, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom
Sanifit Therapeutics S. A.

Completed

Phase 2 Study With SNF472 in Calciphylaxis Patients

Calciphylaxis | Calcific Uremic Arteriolopathy

United States, United Kingdom
Novo Nordisk A/S

Completed

A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects

Healthy Volunteers | Growth Hormone Deficiency

Germany
H. Lundbeck A/S

Completed

A Study Investigating Formulations of Vortioxetine Applied Under the Tongue in Healthy Subjects

Healthy

United Kingdom
Novo Nordisk A/S

Completed

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, United Kingdom, Canada, Austria, Serbia, Germany, South Africa, Malaysia, Czechia
Novo Nordisk A/S

Completed

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, India, Italy, Mexico, Russian Federation, United Kingdom, Spain, Malaysia, Croatia, Greece, Korea, Republic of, Japan, South Africa, Algeria, Thailand, Argentina, Brazil, Canada, Romania
Novo Nordisk A/S

Completed

Awareness, Care & Treatment in Obesity Management (ACTION) Study (ACTION)

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Awareness, Care and Treatment in Obesity Management

Obesity | Metabolism and Nutrition Disorder

Canada
Novo Nordisk A/S

Completed

A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine

Diabetes Mellitus, Type 2

Denmark
Novo Nordisk A/S

Completed

Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Israel, Italy, Mexico, Poland, Russian Federation, Spain, Canada, Denmark, Taiwan, Malaysia, United Kingdom, Turkey, Germany, Bulgaria, Argentina, Australia, Thailand, Algeria, Brazil
Novo Nordisk A/S

Completed

A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, Italy, Puerto Rico, United Kingdom, Argentina, Finland, Serbia, Germany, France, Greece, Netherlands, Switzerland
Novo Nordisk A/S

Completed

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

Germany, France, United States, Japan, Netherlands, Russian Federation, Bulgaria, United Kingdom, North Macedonia, South Africa, Italy, Finland
Novo Nordisk A/S

Completed

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes (onset®8)

Diabetes | Diabetes Mellitus, Type 1

United States, India, Israel, Italy, Japan, Russian Federation, Canada, Austria, Taiwan, Serbia, Germany, Bulgaria, Puerto Rico
Novo Nordisk A/S

Completed

Awareness, Care & Treatment In Obesity Management - An International Observation (ACTION-IO)

Obesity

United Arab Emirates, Australia, Israel, Korea, Republic of, Mexico, Saudi Arabia, Spain, Switzerland, United Kingdom
Novo Nordisk A/S

Terminated

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects (explorer™2)

Healthy | Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United Kingdom, France, Germany
Novo Nordisk A/S

Completed

Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus (EU-TREAT)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Austria, Denmark, Greece, Germany, Switzerland, Italy
Novo Nordisk A/S

Completed

Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Russian Federation, United Kingdom, France, Ukraine
Novo Nordisk A/S

Completed

Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A Survey on Low Blod Sugar Among Insulin-treated Patients With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Turkey, Egypt, Philippines, United Arab Emirates, Bangladesh, Colombia, Singapore, South Africa
Novo Nordisk A/S

Completed

Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes (Jom Mama)

Diabetes Mellitus, Type 2 | Diabetes

Malaysia
Novo Nordisk A/S

Completed

Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A (guardian ™9)

Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United States, Germany, Serbia, Taiwan, Bulgaria
Novo Nordisk A/S

Completed

Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing

Foetal Growth Problem | Small for Gestational Age

Japan
Novo Nordisk A/S

Completed

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy (DUAL™ III)

Diabetes Mellitus, Type 2 | Diabetes

United States, Slovakia, Hungary, France, Australia
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Spain, Hungary, Mexico, Slovakia, Greece, Argentina, South Africa, Australia
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Puerto Rico

3

Subscribe